Further update on proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C
This is a further update on the proposal to fund glecaprevir with pibrentasvir (Maviret) for hepatitis C.
PHARMAC would like to again thank everyone who gave feedback in response to our consultation letter about this proposal, dated 20 July 2018.
PHARMAC provided an update on this proposal on 27 August 2018, which noted that a listing date of 1 October 2018 was not achievable and that we did not have a firm timeframe for when a decision would be made.
This update is to advise that the proposal to list glecaprevir and pibrentasvir (Maviret) is still being reviewed by PHARMAC and that the product will not be listed before the end of the 2018 calendar year.
At this stage, we still do not have a firm timeframe for when a decision will be made or the date at which a listing could occur.
If you have any questions about this update, please email email@example.com.